Codexis, Inc.
Moat Score — Codexis, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Codexis' CodeEvolver directed-evolution platform is a two-decades-old proprietary technology embedded in 18 approved commercial drugs and 15 late-stage clinical candidates, representing real, accumulated intellectual property and know-how. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Codexis is a sub-scale player relative to giants like Novozymes, DSM-Firmenich, and Lonza, and relies partly on outsourced contract manufacturing in Austria, Italy, and the UK, so it has no structural cost advantage over larger competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Once an enzyme is validated inside an FDA-approved manufacturing process, Codexis gains some pricing leverage since switching is costly for the customer, but heavy customer concentration (one customer at 51% of 2025 revenue) constrains how hard it can push. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Enzyme manufacturing technology carries no network effect; one pharma customer adopting Codexis enzymes does not make the product more valuable to another customer. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Because Codexis' enzymes are embedded in regulatory-approved manufacturing processes for 18 commercial drugs, switching to an alternative catalyst would require costly re-validation and re-filing with regulators, creating high genuine switching costs once a drug is approved. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The enzyme-engineering and biocatalysis space includes several credible competitors (Ginkgo Bioworks, BRAIN AG, Enzymicals) plus much larger industrial enzyme makers, so there is no efficient-scale barrier meaningfully protecting Codexis' position. |